Candida endophthalmitis: Focus on current and future antifungal treatment options

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1711-1721

  Khan, Fida A ^a   Slain, Douglas ^b   Khakoo, Rashida A ^c  

^a Ohio Valley Medical Center   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Antifungal agents; Candida; Candidemia; Chorioretinitis; Echinocandin; Endophthalmitis; Fluconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; VORICONAZOLE;

BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA ENDOPHTHALMITIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CHORIORETINITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; EYE EXAMINATION; HUMAN; HYDROPHILICITY; INFECTION RISK; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VITRECTOMY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; ECHINOCANDINS; ENDOPHTHALMITIS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; PYRIMIDINES; RISK FACTORS; TRIAZOLES;

EID: 36849080763     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1711     Document Type: Review

References (83)

1. King GA, Zuravleff JJ, Yu VL. Fungal infections of the eye. In: Anaissie EJ, McGinnis MR, Pfaller MA, eds. Clinical mycology. Philadelphia: Churchill-Livingstone, 2002:566-80.
2. Durand ML, Heier JS. Endophthalmitis. Curr Clin Top Infect Dis 2000;20:271-97.
3. Schiedler V, Scott IU, Flynn HW Jr, et al. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004;137:725-31.
4. Brooks RG. Prospective study of candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989;149:2226-8.
5. Rodriquez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections. Medicine 2003;82:187-202.
6. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia: clinical implications derived from a prospective multicenter study. Ophthalmology 1994;101:1302-9.
7. Bross J, Talbot GH, Maislin G, et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-20.
8. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997;28:185-94.
9. Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine 2003;82:97-105.
10. Flynn HW Jr, Scott IU, Brod RD, Han DP. Current management of endophthalmitis. Int Ophthalmol Clin 2004;44:115-37.
11. Daily MJ, Dickey JB, Packo KH. Endogenous candida endophthalmitis after intravenous anesthesia with propofol. Arch Ophthalmol 1991;109:1081-4.
12. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of candida septicemia: review of seventy-six cases of hematogenous candida endophthalmitis. Medicine 1974;53:47-75.
13. Henderson DK, Edwards JE, Montgomerie JZ. Hematogenous Candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 1981;143:655-61.
14. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy Clin Infect Dis 1998;27:1130-3.
15. Menezes AV, Sigesmund DA, Demajo WA, et al. Mortality of hospitalized patients with candida endophthalmitis. Arch Intern Med 1994;154:2093-7.
16. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44:529-35.
17. Pappas PG, Rex JH, Sobel JD, et al, for the Infectious Diseases Society of America. Guidelines for the treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
18. Edwards JE, Montgomerie JZ, Ishida K, Morrison JO, Guze LB. Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity. J Infect Dis 1977;135:294-7.
19. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992;14:472-8.
20. Krishna R, Amuh D, Lowder CY, et al. Should all patients with candidemia have an ophthalmic examination to rule out ocular candidiasis? Eye 2000;14:30-4.
21. Takebayashi H, Mizota A, Tanaka M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch Clin Exp Ophthalmol 2006;244:816-20.
22. Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1996;27:1012-18.
23. Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster H. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995;119;477-81.
24. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995;20:657-64.
25. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1998;148:2642-5.
26. Smiddy WE. Treatment outcomes of endogenous fungal endophthalmitis. Curr Opin Ophthalmol 1998;9:66-70.
27. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Pharmacology of the eye. Berlin, Germany: Springer-Verlag, 1984:19-116.
28. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into eye and efficacy in experimental candida endophthalmitis. Antimicrob Agents Chemother 1987;31:6-10.
29. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002;46:3719-23.
30. Chignell AH. Endogenous candida endophthalmitis. J R Soc Med 1992;85:721-4.
31. Ghartey KN, Tolentino FI, Freeman HM, McMeel JW, Schepens CL, Aiello LM. Closed vitreous surgery: results and complications of pars plana vitrectomy Arch Ophthalmol 1980;98:1248-52.
32. Souri EN, Green WR. Intravitreal amphotericin B toxicity. Am J Ophthalmol 1974;78:77-81.
33. Kattan H, Pflugfelder SC. Complications of intraocular antimicrobial agents. Int Ophthalmol Clin 1989;29:188-94.
34. Manzouri B, Vafidis GC, Wyse RKH. Pharmacotherapy of fungal eye infections. Expert Opin Pharmacother 2001;2:1849-57.
35. Green WR, Bennett JE, Goos RD. Ocular penetration of amphotericin B. Arch Ophthalmol 1965;73:769-75.
36. O'Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res 1985;4:131-4.
37. Fisher JF, Taylor AT, Clark J, Rao R. Penetration of amphotericin B into human eye. J Infect Dis 1983;147:164.
38. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
39. Griffin JR, Pettit TH, Fishman LS, Foos RY. Blood-borne candida endophthalmitis. Arch Ophthalmol 1973;89:450-6.
40. Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992;15:910-23.
41. O'Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch Ophthalmol 1990;108:1006-8.
42. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
43. Mian UK, Mayers M, Garg Y, et al. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J Ocul Pharmacol Ther 1998;14:459-71.
44. Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994;208:147-56.
45. Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997;3:143-4.
46. Del Palacio A, Cuetara MS, Ferro M, et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993;36:193-9.
47. Filler SG, Crislip MA, Mayer CL, Edwards JE. Comparison of fluconazole and amphotericin B for the treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 1991;35:288-92.
48. Nomura J, Ruskin J. Failure of therapy with fluconazole for candida endophthalmitis. Clin Infect Dis 1993:17:888-9.
49. Drew RH, Perfect JR. Flucytosine. In: Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore: Williams and Wilkins, 1999:651-68.
50. Walsh A, Haft DA, Miller MH, Loran MR, Friedman AH. Ocular penetration of 5-fluorocytosine. Invest Ophthalmol Vis Sci 1978;17:691-4.
51. Richards AB, Jones BR, Whitwell J, Clayton YM. Corneal and intra-ocular infection by Candida albicans treated with 5-fluorocytosine. Trans Ophthalmol Soc UK 1970;89:867-85.
52. Jones BR. Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. Am J Ophthalmol 1975;79:719-51.
53. Robertson DM, Riley FC, Hermans PE. Endogenous candida oculomycosis: report of two patients treated with flucytosine. Arch Ophthalmol 1974;91:33-8.
54. Horne MJ, Ma MH, Taylor RF, Williams R, Zylstra W. Candida endophthalmitis. Med J Aust 1975;1:170-2.
55. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19:306-23.
56. Darling K, Singh J, Wilks D. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). J Infect 2000;40:92-4.
57. Virata SR, Kylstra JA, Brown JC, Wohl DA, Cohen MS. Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B. Clin Infect Dis 1999;28:117-18.
58. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis [online exclusive article]. Clin Infect Dis 2005;41:e27-8. Available from http://www.journals.uchicago.edu/CID/journal/ issues/v41n3/36096/36096.html.
59. Neppert B, Guthoff R, Heidenmann HT. Endogenous candida endophthalmitis in a drug dependent patient: intravenous therapy with liposomal amphotericin B [in German]. Klin Mbl Augenheilk 1992;201:122-4.
60. Pfizer, Inc. Vfend (voriconazole) prescribing information. New York, NY; 2006.
61. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641-5.
62. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-7.
63. Ostrosky-Zeicher L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
64. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004;137:820-5.
65. Varma D, Thaker HR, Moss PJ, Wedgwood K, Innes JR. Use of voriconazole in candida retinitis. Eye 2005;19:485-7.
66. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005;139:135-40.
67. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravueonazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7.
68. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998;42:253-6.
69. Buckland GT, Zerbe B, Unni D, et al. Outcome in systemic Candida albicans in guinea pigs with fluconazole susceptible or resistant strains treated with human equivalent doses of fluconazole or voriconazole [abstract]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2004:abstract M-218.
70. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-5.
71. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003;12:1313-33.
72. Merck & Co. Cancidas (caspofungin acetate) prescribing information. Whitehouse Station, NJ; 2005.
73. Petraitis V, Petraitiene R, Kelaher A, et al. Antifungal activity and safety of caspofungin against experimental disseminated candidiasis in persistently neutropenic rabbits [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:abstract M-188.
74. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11.
75. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
76. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin [online exclusive article]. Clin Infect Dis 2005;40:e46-8. Available from http://www.journals.uchicago.edu/CID/journal/issues/v40n5/34926/34926. html.
77. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001;45:3322-7.
78. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002;46:1857-69.
79. Spellberg BJ, Filler SG, Edwards JE. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006;46:244-51.
80. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005;27:657-73.
81. Okugawa S, Ota Y, Tatsuno K, et al. Clinical efficacy of micafungin in patients with catheter-related bloodstream infections of Candida parapsilosis [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:abstract K-1918.
82. Pfizer, Inc. Eraxis (anidulafungin) prescribing information. New York, NY; 2006.
83. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001;45:2845-55.